1
However, the stimuli to AVP is likely different between cycling and running.
2
Results: Twenty-two patients were found to carry a pathogenic AVP-NPII gene mutation.
3
One AVP patient developed acute coronary syndrome with dose-dependent ECG changes.
4
No differences were found for non-social working memory or for AVP vs placebo.
5
We assessed the results of vascular embolization obtained using the AVP.
6
The magnitude of the AVP-induced vasoconstriction was significantly reduced by calphostin-C.
7
The modest decrease in PV was not the primary non-osmotic stimulus to AVP.
8
The contents of SS and AVP in hippocampus tissue were measured by radioimmunoassay.
9
Conclusions: Peripheral embolization with the AVP 4 was successful in the majority of patients.
10
At the maximum effect, pinacidil completely relaxed vasoconstriction in the continuing exposure to AVP.
11
These results suggest that periventricular dopaminergic mechanisms may act to inhibit hemorrhage-induced AVP secretion.
12
The copeptin assay may be a useful alternative to direct measurement of AVP concentration.
13
This study evaluated the AVP 4 in peripheral vascular embolization.
14
Measurement of AVP levels has limitations due to its short half-life and cumbersome detection method.
15
In ICU patients, AVP decreased to moderately elevated levels within 24 h after ED admission.
16
It has been proposed that this is because AVP facilitates baroreflex control of the circulation.